Triumvera, co-founded by McMaster's professor Jonathan Bramson, looks to progress its solid tumour therapeutic candidate.

Triumvira Immunologics, a US-based cancer therapeutics developer co-founded by McMaster University faculty, expanded its series A round to $100m yesterday. The $45m extension featured Leaps by Bayer, the impact corporate venturing arm of pharmaceutical and chemicals group Bayer, Multiple Myeloma Research Foundation’s venture philanthropy subsidiary, B Capital Group, Atem Capital, Myeloma Investment Fund, Northpond Ventures…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.